Associate Professor Heather Cunliffe

Contact Details

Phone: 64 3 479 5060
Email: heather.cunliffe@otago.ac.nz

University Links

Position

Associate Professor

Department

Department of Pathology and Molecular Medicine (Dunedin)

Qualifications

BSc(Hons) PhD

Research summary

Translational biomarker discovery in breast and ovarian cancer

Teaching

GENE 360 Special Topics in Genetics
GENE 411 Current Topics in Genetics (Course Convenor)
MELS 304 Principles of Pathology
MICN 201 Medicine Second Year
MICN 301 Medicine Third Year
PATH 201 Foundations in Human Pathology
PATH 301 Advanced Pathology
PATH 302 Cancer Biology (Course Convenor)

Memberships

Member, Health Research South Board
Member, Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Active Member, American Association for Cancer Research (AACR)
Member, AACR-Women in Cancer Research
Member, New Zealand Society for Biochemistry and Molecular Biology

Research

The focus of Associate Professor Cunliffe's research is the discovery and validation of biomarkers that will impact therapeutic decision-making and improve treatment outcomes for breast cancer and ovarian cancer patients. Her laboratory leverages genomic, biochemical, and cell-biologic approaches to define and target the pathobiology driving malignant progression in treatment-refractory tumour contexts.

Current areas of interest include:

Defining drivers of triple negative breast cancer metastasis
The molecular underpinnings of inflammatory breast cancer
Identifying tractable therapeutic targets in uncommon and rare ovarian tumours
Understanding drivers of chemoresistance in epithelial ovarian cancer

Associate Professor Cunliffe also has an interest and significant expertise in biospecimen science to empower genomics-enabled medicine.

Biography

Associate Professor Cunliffe completed her undergraduate training at Victoria University of Wellington and received her PhD in Biochemistry and Molecular Biology from the University of Otago. She then trained as a Postdoctoral Fellow from 1999–2004 in the Cancer Genetics Branch of the National Human Genome Research Institute, at the National Institutes of Health, in Bethesda, MD, USA. In 2004, Associate Professor Cunliffe joined the research faculty at the Translational Genomics Research Institute (TGen), a not-for-profit biomedical research institute in Phoenix Arizona, where she headed the Breast and Ovarian Cancer Research Unit for 10 years prior to returning to the University of Otago.

Additional details

Specialty Chief Editor, Frontiers in Cancer Genetics
Honorary Lifetime Member, Board of Directors, Anne Rita Monahan Foundation
Founding Board Member, Ovarian Cancer Alliance of Arizona

Publications

Onuma, A., Davis, W., & Cunliffe, H. (2026, October). Investigating the role of fibroblast growth factor inducible 14 in HER2-positive breast cancer. Poster session presented at the Te Pūao Mātai Pukupuku New Zealand Society for Oncology 56th Annual Conference, Wellington, New Zealand. Conference Contribution - Poster Presentation (not in published proceedings)

Lilly, M., Davis, W., & Cunliffe, H. (2026, October). Investigating receptor tyrosine kinase activity to identify potential therapeutic strategies in low-grade serous ovarian cancer. Poster session presented at the Te Pūao Mātai Pukupuku New Zealand Society for Oncology 56th Annual Conference, Wellington, New Zealand. Conference Contribution - Poster Presentation (not in published proceedings)

Davis, W., Ludemann, J., Lilly, M., Cunliffe, H., on behalf of the International Consortium for Low-Grade Serous Ovarian Cancer (ICLC). (2026, October). From molecular profiling to therapeutic discovery: An international consortium approach to low-grade serous ovarian cancer. Poster session presented at the Te Pūao Mātai Pukupuku New Zealand Society for Oncology 56th Annual Conference, Wellington, New Zealand. Conference Contribution - Poster Presentation (not in published proceedings)

Grisham, R. N., Slomovitz, B., Podder, V., Sun, C., Andrews, N., Manning-Geist, B., … Cunliffe, H. E., … Gershenson, D. M. (2026). Low-grade serous ovarian cancer: 2026 expert consensus report [Invited review]. Gynecologic Oncology, 214, 144-163. doi: 10.1016/j.ygyno.2026.10.011 Journal - Research Article

Chen, R. M., Ludgate, J. L., Weeks, R. J., Cunliffe, H. E., Dohan, A. G., & Morison, I. M. (2026). The myeloma risk variant of TNFRSF13B shows reduced NF-κB signaling activity in HEK293 cells. European Journal of Haematology. Advance online publication. doi: 10.1111/ejh.70283 Journal - Research Article

2026

Journal - Research Article

Conference Contribution - Poster Presentation (not in published proceedings)

2025

Journal - Research Article

McQueen, S., Chin, W. Q., Cunliffe, H. E., & McDonald, F. J. (2025). Stable overexpression of the epithelial sodium channel alpha subunit reduces migration and proliferation in breast cancer cells. Breast Cancer Research & Treatment, 211, 595-604. doi: 10.1007/s10549-025-07667-w

2024

Conference Contribution - Published proceedings: Abstract

Sun, C., Andrews, N., Ludemann, J., Larsen, E., Mackay, C., de Fazio, A., … Cunliffe, H., … Gershenson, D. (2024). Voices of women with low-grade serous ovarian cancer: Results from a multinational survey. Gynecologic Oncology, 190, (pp. S377-S378). doi: 10.1016/j.ygyno.2024.07.560

Conference Contribution - Poster Presentation (not in published proceedings)

Singh, P., McDonald, F., & Cunliffe, H. (2024, August-September). α-ENaC influence on sensitivity towards chemotherapy drugs in breast cancer and immune response. Poster session presented at the 18th New Zealand Medical Sciences Congress (MedSci), Queenstown, New Zealand.

2023

Journal - Research Article

Reader, K. L., John-McHaffie, S., Zellhuber-McMillan, S., Jowett, T., Mottershead, D. G., Cunliffe, H. E., & Gold, E. J. (2023). Activin B and activin C have opposing effects on prostate cancer progression and cell growth. Cancers, 15, 147. doi: 10.3390/cancers15010147

Journal - Research Other

Ratajska, M., Sette, C., & Cunliffe, H. E. (2023). 365 days of progress in cancer genetics. Frontiers in Oncology, 13. doi: 10.3389/fonc.2023.1270902

Conference Contribution - Published proceedings: Abstract

McQueen, S., Ware, A., Cunliffe, H., & McDonald, F. (2023). Overexpression of the alpha subunit of the epithelial sodium channel in MDAMB231 breast cancer cells reduces cell migration and proliferation. Cancer Research, 83(Suppl. 5), P2-16-07. doi: 10.1158/1538-7445.SABCS22-P2-16-07

Conference Contribution - Poster Presentation (not in published proceedings)

Jasiak, A., Anderson, L., Neumann, S., Wasag, B., Weeks, R., Walker, L., Cunliffe, H., & Ratajska, M. (2023, September). Adaptive homeostasis as a possible non-genetic regulator of BRCA1/2 splicing in ovarian cancer. Poster session presented at the New Zealand Society for Oncology (NZSO) Conference, Napier, New Zealand.

2022

Journal - Research Other

Naro, C., Cunliffe, H. E., & Sette, C. (2022). Insight in cancer genetics: 2022. Frontiers in Oncology, 12, 988310. doi: 10.3389/fonc.2022.988310

Conference Contribution - Published proceedings: Abstract

McQueen, S. R. A., Cunliffe, H. E., & McDonald, F. J. (2022). Alpha-ENaC overexpression in MDAMB231 breast cancer cells reduces cell migration and proliferation. In L. Wilson, H. Harcombe, P. Jayakaran, L. Burga, J. Antony, K. Morgaine, M. Garelja, A. Middleton, M. Anwar & T. Milne (Eds.), Proceedings of the 263rd Otago Medical School Research Society (OMSRS) Meeting: PhD Student Speaker Awards. Dunedin, New Zealand: OMSRS. Retrieved from https://ourarchive.otago.ac.nz/handle/10523/12839

Conference Contribution - Poster Presentation (not in published proceedings)

Ware, A. W., Cheung, T. T., McQueen, S. R. A., Chin, W. Q., Cunliffe, H. E., & McDonald, F. J. (2022, August-September). The role of the epithelial sodium channel (ENaC) in breast cancer. Poster session presented at the 16th New Zealand Medical Sciences Congress (MedSci), Queenstown, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

McDonald, F. J., Harris, J. J., Slatter, T. L., Cunliffe, H. E., & Ware, A. W. (2022, August). Epithelial sodium channel regulates breast cancer cell proliferation. Verbal presentation at the Cancer Satellite Meeting: Queenstown Research Week, Queenstown, New Zealand.

McQueen, S. R. A., Cunliffe, H. E., & McDonald, F. J. (2022, August-September). Alpha-ENaC overexpression in MDAMB231 breast cancer cells reduces cell migration and proliferation. Verbal presentation at the 16th New Zealand Medical Sciences Congress (MedSci), Queenstown, New Zealand.

2021

Journal - Research Article

Ware, A. W., Harris, J. J., Slatter, T. L., Cunliffe, H. E., & McDonald, F. J. (2021). The epithelial sodium channel has a role in breast cancer cell proliferation. Breast Cancer Research & Treatment, 187, 31-43. doi: 10.1007/s10549-021-06133-7

Conference Contribution - Published proceedings: Abstract

McQueen, S., Ware, A., Cunliffe, H., & McDonald, F. (2021). The influence of the epithelial sodium channel in breast cancer cells. FASEB Journal, 35(Suppl. 1). doi: 10.1096/fasebj.2021.35.S1.05028

Conference Contribution - Verbal presentation and other Conference outputs

Cunliffe, H. E. (2021, November). Investigating the clinical significance of fibroblast growth factor inducible 14 in breast cancer. Verbal presentation at the New Zealand Breast Cancer Symposium (NZBCS), [Online].

2020

Journal - Research Article

Kee, D., Parker, C., Bae, S., Tucker, K. M., Harrison, M., Tohidi-Esfahani, I., … Cunliffe, H. E., … Scott, C. L. (2020). CART-WHEEL.org: An ethically approved online database for patient-entered data to facilitate rare cancer research. JCO Clinical Cancer Informatics, 4, 136-146. doi: 10.1200/cci.19.00085

Mehta, S., McKinney, C., Algie, M., Verma, C. S., Kannan, S., Harfoot, R., … Gould, M. L., Parker, K., … Cunliffe, H. E., … Kleffmann, T., Braithwaite, A. W., & Woolley, A. G. (2020). Dephosphorylation of YB-1 is required for nuclear localisation during G₂ phase of the cell cycle. Cancers, 12(2), 315. doi: 10.3390/cancers12020315

Conference Contribution - Published proceedings: Abstract

Hoppe, R., Kandabarau, S., Fan, P., Winter, S., Abderrahman, B., Cunliffe, H., … Brauch, H. B. (2020). Genome-wide DNA methylation changes in AI-resistant breast cancer models during E2-treatment. Cancer Research, 80(16, Suppl.), 144. doi: 10.1158/1538-7445.Am2020-144

2019

Journal - Research Article

Mehta-Mujoo, P. P., Cunliffe, H. E., Hung, N. A., & Slatter, T. L. (2019). Long non-coding RNA ANRIL in the nucleus associates with periostin expression in breast cancer. Frontiers in Oncology, 9, 885. doi: 10.3389/fonc.2019.00885

Conference Contribution - Published proceedings: Abstract

Hoppe, R., Kandabarau, S., Fan, P., Jordan, V. C., Cunliffe, H., & Brauch, H. B. (2019). Comparative whole genome analyses of breast cancer aromatase inhibitor resistance models. Cancer Research, 79(13, Suppl.), 1689. doi: 10.1158/1538-7445.Am2019-1689

2018

Journal - Research Article

Mehta, S. Y., Morten, B. C., Antony, J., Henderson, L., Lasham, A., Campbell, H., Cunliffe, H., Horsfield, J. A., … Braithwaite, A. W. (2018). Regulation of the interferon-gamma (IFN-γ) pathway by p63 and Δ133p53 isoform in different breast cancer subtypes. Oncotarget, 9(49), 29146-29161. doi: 10.18632/oncotarget.25635

Conference Contribution - Published proceedings: Abstract

Harris, J., Black, M., Miller, L., & Cunliffe, H. (2018). Investigating the clinical significance of Fibroblast Growth Factor Inducible 14 in breast cancer. Proceedings of the New Zealand Society for Oncology (NZSO) Conference. Retrieved from http://www.nzsoncology.org.nz/

Conference Contribution - Poster Presentation (not in published proceedings)

Harris, J. J., Black, M. A., Miller, L. D., & Cunliffe, H. E. (2018, August). Investigating the clinical significance of Fibroblast Growth Factor Inducible 14 in breast cancer. Poster session presented at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.

Rajesh, A., Jones, N., Stuart, G., Cunliffe, H., Wise, L., & Hibma, M. (2018, September). Investigating the role of Langerhans cells during wound healing. Poster session presented at the Otago Spotlight Symposium on Infectious Disease, Wellington, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Ware, A. W., McQueen, S., Cunliffe, H., Fronius, M., & McDonald, F. J. (2018, August). Epithelial sodium channel, ENaC, as a potential therapeutic target for breast cancer. Verbal presentation at the Medical Sciences Congress (MedSci), Queenstown, New Zealand.

2017

Conference Contribution - Published proceedings: Abstract

Harris, J., Stone, A., & Cunliffe, H. (2017). Investigating the anti-invasive role of dexamethasone in triple negative breast cancer. Proceedings of the University of Otago Student Research Symposium: Te Wānaka Rakahau: Ākoka. (pp. 32). Retrieved from http://www.otago.ac.nz/graduate-research/scholarships/otago643219.html

Conference Contribution - Verbal presentation and other Conference outputs

Rajesh, A., Cunliffe, H., Wise, L., & Hibma, M. (2017, July). Role of Langerhans cells in wound healing. Verbal presentation at the New Zealand Branch of the Australasian Society for Immunology (NZ ASI) Annual Scientific Meeting, Christchurch, New Zealand.

2016

Journal - Research Article

Hoppe, R., Fan, P., Büttner, F., Winter, S., Tyagi, A. K., Cunliffe, H., … Brauch, H. (2016). Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget, 7(44), 71235-71254. doi: 10.18632/oncotarget.12103

Witkowski, L., Goudie, C., Ramos, P., Boshari, T., Brunet, J.-S., Karnezis, A. N., … Cunliffe, H., … Foulkes, W. D. (2016). The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type. Gynecologic Oncology, 141, 454-460. doi: 10.1016/j.ygyno.2016.03.013

Conference Contribution - Published proceedings: Abstract

Hoppe, R., Fan, P., Büttner, F., Winter, S., Cunliffe, H., Jordan, V. C., & Brauch, H. G. (2016). Modulation of aromatase inhibitor resistance by miRNAs in breast cancer. Cancer Research, 76(14, Suppl.), 1073. doi: 10.1158/1538-7445.AM2016-1073

2015

Journal - Research Article

Barrett, M. T., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., … Pockaj, B. A. (2015). Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. Oncotarget, 6(28). doi: 10.18632/oncotarget.4494

Fan, P., Cunliffe, H. E., Maximov, P. Y., Agboke, F. A., McDaniel, R. E., Zou, X., … Jordan, V. C. (2015). Integration of downstream signals of insulin-like growth factor-1 receptor by endoplasmic reticulum stress for estrogen-induced growth or apoptosis in breast cancer cells. Molecular Cancer Research, 13(10), 1367-1376. doi: 10.1158/1541-7786.mcr-14-0494

Necela, B. M., Crozier, J. A., Andorfer, C. A., Lewis-Tuffin, L., Kachergus, J. M., Geiger, X. J., … Cunliffe, H. E., … Perez, E. A. (2015). Folate receptor-α (FOLR1) expression and function in triple negative tumors. PLoS ONE, 10(3), e0122209. doi: 10.1371/journal.pone.0122209

Conference Contribution - Published proceedings: Abstract

Andreozzi, M., Francis, P., Lenkiewicz, E., Champion, M., Laughlin, B., Anderson, K., Cunliffe, H., … Pockaj, B. (2015). Deep clonal profiling identifies distinct mechanisms of heterogeneity and evolution in breast cancer. Cancer Research, 75(15, Suppl.), LB-175. doi: 10.1158/1538-7445.AM2015-LB-175

Conference Contribution - Verbal presentation and other Conference outputs

Cunliffe, H. (2015, October). Molecularly-informed treatment strategies in breast and ovarian cancer. Verbal presentation at the Otago Spotlight Series: Cancer Research, Wellington, New Zealand.

2014

Journal - Research Article

McGhan, L. J., McCullough, A. E., Protheroe, C. A., Dueck, A. C., Lee, J. J., Nunez-Nateras, R., … Cunliffe, H. E., & Pockaj, B. A. (2014). Androgen receptor-positive triple negative breast cancer: A unique breast cancer subtype. Annals of Surgical Oncology, 21, 361-367. doi: 10.1245/s10434-013-3260-7

Ramos, P., Karnezis, A. N., Hendricks, W. P. D., Wang, Y., Tembe, W., Zismann, V. L., … Cunliffe, H. E., … Trent, J. M. (2014). Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Rare Diseases, 2(1), e967148. doi: 10.4161/2167549X.2014.967148

Reese, J. M., Suman, V. J., Subramaniam, M., Wu, X., Negron, V., Gingery, A., … Cunliffe, H. E., … Hawse, J. R. (2014). ERβ1: Characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer. BMC Cancer, 14, 749. doi: 10.1186/1471-2407-14-749

Fan, P., Agboke, F. A., Cunliffe, H. E., Ramos, P., & Jordan, V. C. (2014). A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. European Journal of Cancer, 50(16), 2866-2876. doi: 10.1016/j.ejca.2014.08.011

Fan, P., Cunliffe, H. E., Griffith, O. L., Agboke, F. A., Ramos, P., Gray, J. W., & Jordan, V. C. (2014). Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. European Journal of Cancer, 50(16), 2877-2886. doi: 10.1016/j.ejca.2014.08.010

Ramos, P., Karnezis, A. N., Craig, D. W., Sekulic, A., Russell, M. L., Hendricks, W. P. D., … Cunliffe, H. E., … Trent, J. M. (2014). Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nature Genetics, 46(5), 427-429. doi: 10.1038/ng.2928

Conference Contribution - Published proceedings: Abstract

Hawse, J. R., Subramaniam, M., Reese, J. M., Wu, X., Negron, V., Gingery, A., … Cunliffe, H. E., … Ingle, J. N. (2014). ERβ and breast cancer: A potential predictive and prognostic biomarker and novel therapeutic drug target. Proceedings of the San Antonio Breast Cancer Symposium. Retrieved from http://www.abstracts2view.com/sabcs13/view.php?nu=SABCS13L_776&terms=

Pockaj, B., McCullough, A. E., Cunliffe, H. E., Anderson, K. S., Gonzalez, L. G., Alvarez, M. L., & Barrett, M. T. (2014). Phosphatidylinositol 3-kinase (PI3-kinase) pathway aberrations are frequently seen in triple-negative breast cancer. Annals of Surgical Oncology, 21(1, Suppl.), (pp. S63). [Abstract]

Ramos, P., Karnezis, A., Craig, D., Sekulic, A., Russell, M., Hendricks, W., … Cunliffe, H., … Trent, J. (2014). The rare, highly malignant small cell carcinoma of the ovary displays common inactivating germline and somatic mutations in the tumor suppressor SMARCA4. Proceedings of the American Association for Cancer Research (AACR) 105th Annual Meeting. Retrieved from http://www.aacr.org/home/scientists/meetings--workshops/aacr-annual-meeting-2014.aspx

Conference Contribution - Verbal presentation and other Conference outputs

Cunliffe, H. E., Alvarez, M. L., Lenkiewicz, E., Holley, T., Evers, L., Dueck, A., … Barrett, M. T. (2014, October). Genomic context and clinical significance of androgen receptor positive triple negative breast cancer. Invited presentation at the New Zealand Society for Oncology (NZSO) Conference, Tauranga, New Zealand.

2013

Journal - Research Article

Katchman, B. A., Ocal, I. T., Cunliffe, H. E., Chang, Y.-H., Hostetter, G., Watanabe, A., … Lake, D. F. (2013). Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer. Breast Cancer Research, 15, R28. doi: 10.1186/bcr3407

Nokes, B. T., Cunliffe, H. E., LaFleur, B., Mount, D., Livingston, R. B., Futscher, B. W., & Lang, J. E. (2013). In vitro assessment of the inflammatory breast cancer cell line SUM 149: Discovery of 2 single nucleotide polymorphisms in the RNase L Gene. Journal of Cancer, 4(2), 104-116. doi: 10.7150/jca.5002

Rowton, M., Ramos, P., Anderson, D. M., Rhee, J. M., Cunliffe, H. E., & Rawls, A. (2013). Regulation of mesenchymal-to-epithelial transition by PARAXIS during somitogenesis. Developmental Dynamics, 242, 1332-1344.

Conference Contribution - Published proceedings: Abstract

Crozier, J. A., Necela, B. M., Thompson, E. A., Geiger, X., Moreno-Aspitia, A., McCullough, A. E., … Cunliffe, H., … Perez, E. A. (2013). Increased expression of folate receptor-α (FRA) in triple-negative breast cancer: A potential therapeutic target. Journal of Clinical Oncology, 31(Suppl.), 1037. Retrieved from http://meetinglibrary.asco.org/print/1153831

2012

Journal - Research Article

Asmann, Y. W., Necela, B. M., Kalari, K. R., Hossain, A., Baker, T. R., Carr, J. M., … Cunliffe, H. E., … Thompson, E. A. (2012). Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer. Cancer Research, 72(8), 1921-1928. doi: 10.1158/0008-5472.CAN-11-3142

Kimbung, S., Biskup, E., Johansson, I., Aaltonen, K., Ottosson-Wadlund, A., Gruvberger-Saal, S., Cunliffe, H., … Hedenfalk, I. (2012). Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters, 319, 232-241. doi: 10.1016/j.canlet.2012.01.015

Cunliffe, H. E., Jiang, Y., Fornace, K. M., Yang, F., & Meltzer, P. S. (2012). PAR6B is required for tight junction formation and activated PKCζ localization in breast cancer. American Journal of Cancer Research, 2(5), 478-491.

Holley, T., Lenkiewicz, E., Evers, L., Tembe, W., Ruiz, C., Gsponer, J. R., … Cunliffe, H. E., … Barrett, M. T. (2012). Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS ONE, 7(1), e50586. doi: 10.1371/journal.pone.0050586

Conference Contribution - Published proceedings: Abstract

Ramos, P., Russell, M. L., Nordstrom, L., Smith, S., Barrett, M. T., Holley, T., … Cunliffe, H. E. (2012). Molecular characterization of small cell carcinoma of the ovary. Proceedings of the American Society of Human Genetics Annual Meeting. Retrieved from http://www.ashg.org/2012meeting/abstracts/fulltext/f120123448.htm

Katchman, B. A., Ocal, T., Hostetter, G., Cunliffe, H. E., Watanabe, A., & Lake, D. F. (2012). Expression of quiescin sulfhydryl oxidase 1 is associated with a highly invasive phenotype and correlates with a poor prognosis in Luminal B breast cancer. Cancer Research, 72(24, Suppl. 3), P1-05-04. doi: 10.1158/0008-5472.SABCS12-P1-05-04

2011

Journal - Research Article

Ariazi, E. A., Cunliffe, H. E., Lewis-Wambi, J. S., Slifker, M. J., Willis, A. L., Ramos, P., … Jordan, V. C. (2011). Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. PNAS, 108(47), 18879-18886. doi: 10.1073/pnas.1115188108

Conference Contribution - Published proceedings: Full paper

Jordan, V. C., Obiorah, I., Fan, P., Kim, H. R., Ariazi, E., Cunliffe, H., & Brauch, H. (2011). The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: Consequences and opportunities. Breast, 20(Suppl. 3), (pp. S1-S11). doi: 10.1016/S0960-9776(11)70287-9

Nasser, S., Cunliffe, H. E., Black, M. A., & Kim, S. (2011). Context-specific gene regulatory networks subdivide intrinsic subtypes of breast cancer. BMC Bioinformatics. 12(Suppl. 2), S3. doi: 10.1186/1471-2105-12-S2-S3

Conference Contribution - Published proceedings: Abstract

Felding-Habermann, B., O'Sullivan, D. M., Lorger, M., MacDermed, D., Fernandez-Santidrian, A., Steele, J. B., … Cunliffe, H., & Vaughn, S. (2011). Breast cancer heterogeneity and treatment resistance: Clues from metaplastic tumors. Cancer Research, 71(24, Suppl.), PD03-37. doi: 10.1158/0008-5472.SABCS11-PD03-07

2010

Journal - Research Article

Rennstam, K., Ringberg, A., Cunliffe, H. E., Olsson, H., Landberg, G., & Hedenfalk, I. (2010). Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency. Genes Chromosomes & Cancer, 49(1), 78-90. doi: 10.1002/gcc.20723

Ariazi, E. A., Brailoiu, E., Yerrum, S., Shupp, H. A., Slifker, M. J., Cunliffe, H. E., Black, M. A., … Jordan, V. C. (2010). The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Research, 70(3), 1184-1194. doi: 10.1158/0008-5472.CAN-09-3068

Conference Contribution - Published proceedings: Abstract

Rowton, M., Ramos, P., Anderson, D., Cunliffe, H., & Rawls, A. (2010). The regulation of somite epithelialization by paraxis. Developmental Biology, 344(1), (pp. 461). doi: 10.1016/j.ydbio.2010.05.197

2009

Conference Contribution - Published proceedings: Abstract

Anderson, E. M., Getz, J. E., Balagurunathan, Y., Black, M. A., Willis, A. L., Hyder, P., … Cunliffe, H. E. (2009). Investigation of VAV3 as a novel biomarker and indicator of chemosensitivity in basal-like breast cancer. Proceedings of the American Association for Cancer Research (AACR) 100th Annual Meeting. Retrieved from http://www.aacrmeetingabstracts.org/

2008

Journal - Research Article

Lewis-Wambi, J. S., Cunliffe, H. E., Kim, H. R., Willis, A. L., & Jordan, V. C. (2008). Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells. European Journal of Cancer, 44(12), 1770-1779. doi: 10.1016/j.ejca.2008.05.016

Willis, A. L., Tran, N. L., Chatigny, J. M., Charlton, N., Vu, H., Brown, S. A. N., Black, M. A., … Cunliffe, H. E. (2008). The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Molecular Cancer Research, 6(5), 725-734. doi: 10.1158/1541-7786.MCR-08-0005

2007

Journal - Research Article

Winkles, J. A., Tran, N. L., Brown, S. A. N., Stains, N., Cunliffe, H. E., & Berens, M. E. (2007). Role of TWEAK and Fn14 in tumor biology. Frontiers in Bioscience, 12, 2761-2771.

Journal - Research Other

Jordan, V. C., Ariazi, E. A., Lewis-Wambi, J. S., Swaby, R. R., Cunliffe, H. E., Riegel, A. T., & Wellstein, A. (2007). Oestrogen is bad for patients with breast cancer? [Short communication]. Breast Cancer Research, 9(Suppl. 2), S22.

Conference Contribution - Published proceedings: Full paper

Jordan, V. C., Lewis-Wambi, J., Kim, H., Cunliffe, H., Ariazi, E., Sharma, C. G. N., … Swaby, R. (2007). Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients. Breast, 16(Suppl. 2), (pp. S105-S113). doi: 10.1016/j.breast.2007.07.020

2006

Journal - Research Article

Tran, N. L., McDonough, W. S., Savitch, B. A., Fortin, S. P., Winkles, J. A., Symons, M., … Cunliffe, H. E., … Berens, M. E. (2006). Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-κB and correlate with poor patient outcome. Cancer Research, 66(19), 9535-9542. doi: 10.1158/0008-5472.CAN-06-0418

Gruvberger-Saal, S. K., Cunliffe, H. E., Carr, K. M., & Hedenfalk, I. A. (2006). Microarrays in breast cancer research and clinical practice: The future lies ahead. Endocrine-Related Cancer, 13(4), 1017-1031. doi: 10.1677/erc.1.01246

Conference Contribution - Published proceedings: Abstract

Kamradt, J., Cunliffe, H., Wullich, B., Stöckle, M., & Meltzer, P. (2006). Hormone treatment alters expression of RNAseL and oligoadenylate synthetases in hormone-sensitive prostate cells. European Urology Supplements, 5(2), (pp. 125). doi: 10.1016/S1569-9056(06)60418-1

2003

Journal - Research Article

Cunliffe, H. E., Ringnér, M., Bilke, S., Walker, R. L., Cheung, J. M., Chen, Y., & Meltzer, P. S. (2003). The gene expression response of breast cancer to growth regulators: Patterns and correlation with tumor expression profiles. Cancer Research, 63(21), 7158-7166.

2001

Journal - Research Article

Scherr, M., LeBon, J., Castanotto, D., Cunliffe, H. E., Meltzer, P. S., Ganser, A., … Rossi, J. J. (2001). Detection of antisense and ribozyme accessible sites on native mRNAs: Application to NCOA3 mRNA. Molecular Therapy, 4(5), 454-460. doi: 10.1006/mthe.2001.0481

Azorsa, D. O., Cunliffe, H. E., & Meltzer, P. S. (2001). Association of steroid receptor coactivator AIB1 with estrogen receptor-α in breast cancer cells. Breast Cancer Research & Treatment, 70, 89-101. doi: 10.1023/A:1012972808558

Wilderman, P. J., Vasil, A. I., Johnson, Z., Wilson, M. J., Cunliffe, H. E., Lamont, I. L., & Vasil, M. L. (2001). Characterization of an endoprotease (PrpL) encoded by a PvdS-regulated gene in Pseudomonas aeruginosa. Infection & Immunity, 69(9), 5385-5394.

2000

Journal - Research Article

Porteous, S., Torban, E., Cho, N.-P., Cunliffe, H. E., Chua, L. J., McNoe, L. A., Ward, T. A., … Yun, K., … Eccles, M. R. (2000). Primary renal hypoplasia in humans and mice with PAX2 mutations: Evidence of increased apoptosis in fetal kidneys of PAX2(1NEU)+/-mutant mice. Human Molecular Genetics, 9(1), 1-11.

1999

Conference Contribution - Published proceedings: Abstract

Eccles, M. R., Cho, N.-P., Torban, E., Cunliffe, H. E., Favor, J., Porteous, S., & Goodyer, P. R. (1999). Towards a molecular basis for understanding renal abnormalities and PAX2 haploinsufficiency in renal-coloboma syndrome. Journal of the American Society of Nephrology. 10(A2037), (pp. 404A). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Eccles, M. R., Cho, N.-P., Torban, E., Cunliffe, H. E., Favor, J., Porteous, S., & Goodyer, P. R. (1999). Towards a molecular basis for understanding renal abnormalities and PAX2 haploinsufficiency in renal-coloboma syndrome. Verbal presentation at the American Society of Nephrology Conference, Miami, USA.

1998

Journal - Research Article

Stayner, C. K., Cunliffe, H. E., Ward, T. A., & Eccles, M. R. (1998). Cloning and characterization of the human PAX2 promoter. Journal of Biological Chemistry, 273(39), 25472-25479.

Cunliffe, H. E., McNoe, L. A., Ward, T. A., Devriendt, K., Brunner, H. G., & Eccles, M. R. (1998). The prevalence of PAX2 mutations in patients with isolated colobomas or colobomas associated with urogenital anomalies. Journal of Medical Genetics, 35(10), 806-812.

Conference Contribution - Verbal presentation and other Conference outputs

Porteous, S., Cho, N.-P., Cunliffe, H. E., Yoon, H.-S., Ward, T. A., Favor, J., & Eccles, M. R. (1998). Characterization of the molecular pathological basis of renal abnormalities in PAX2 haploinsufficiency syndrome. Verbal presentation at the Queenstown Molecular Biology Conference, Queenstown.

Porteous, S., Cho, N.-P., Cunliffe, H. E., Yoon, H.-S., Ward, T. A., Favor, J., & Eccles, M. R. (1998). Characterization of the molecular pathological basis of renal abnormalities in PAX2 haploinsufficiency syndrome. Verbal presentation at the Human Genetics Society of Australasia Conference, Christchurch.

1997

Journal - Research Article

McConnell, M. J., Cunliffe, H. E., Chua, L. J., Ward, T. A., & Eccles, M. R. (1997). Differential regulation of the human Wilms-tumour suppressor gene (WT1) promoter by two isoforms of PAX2. Oncogene, 14(22), 2689-2700. doi: 10.1038/sj.onc.1201114

Schimmenti, L. A., Cunliffe, H. E., McNoe, L. A., Ward, T. A., French, M., Shim, H. H., … Eccles, M. R. (1997). Further delineation of renal-coloboma syndrome in patients with extreme variability of phenotype and identical PAX2 mutations. American Journal of Human Genetics, 60(4), 869-878.

Conference Contribution - Published proceedings: Abstract

Eccles, M. R., McNoe, L. A., Ward, T. A., Brunner, H. G., & Cunliffe, H. E. (1997). PAX2 mutation identified in a patient with renal-coloboma syndrome and vesicoureteric reflux (VUR): Analysis of 43 patients with coloboma and/or urogenital anomalies. American Journal of Human Genetics. 61(4), (pp. 1941). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Eccles, M. R., McConnell, M., French, M., & Cunliffe, H. E. (1997). Transactivation of the WT1 promoter by PAX2, and co-expression of PAX2 and WT1 transcripts in Wilms Tumour. Verbal presentation at the Transcriptional Control of Proliferation, DIfferentiation, and Development AACR Conference, New York.

McNoe, L. A., Cunliffe, H. E., Ward, T. A., French, M., Brunner, H. G., Schimmenti, H. E., & Eccles, M. R. (1997). PAX2 mutation identified in a patient with renal-coloboma syndrome and vesicoureteric reflux (VUR): Analysis of 99 patients with coloboma and/or urogenital anomalies. Verbal presentation at the American Society of Human Genetics Conference, Baltimore.

1996

Journal - Research Article

Ochsner, O. A., Johnson, Z., Lamont, I. L., Cunliffe, H. E., & Vasil, M. L. (1996). Exotoxin A production in Pseudomonas aeruginosa requires the iron-regulated pvdS gene encoding an alternative sigma factor. Molecular Microbiology, 21(5), 1019-1028. doi: 10.1046/j.1365-2958.1996.481425.x

1995

Journal - Research Article

Cunliffe, H. E., Merriman, T. R., & Lamont, I. L. (1995). Cloning and characterization of pvdS, a gene required for pyoverdine synthesis in Pseudomonas aeruginosa: PvdS is probably an alternative sigma factor. Journal of Bacteriology, 177(10), 2744-2750. doi: 10.1128/jb.177.10.2744-2750.1995